Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NUVL
NUVL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NUVL News
S&P 500 Futures Decline in Pre-Market Trading; Nuvalent and Figure Tech Solutions Take the Lead
5d ago
Barron's
Nuvalent (NUVL.US) Executive Plans to Sell $5.73 Million in Common Stock via Form 144
6d ago
moomoo
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Mar 17 2026
PRnewswire
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Mar 17 2026
Newsfilter
Vestal Point Capital Sells Nuvalent Shares Worth $103.93 Million
Mar 17 2026
Fool
Vestal Point Capital Sells Nuvalent Shares Worth $103.93 Million
Mar 17 2026
NASDAQ.COM
S&P 500 Futures Decline in Pre-Market Session; MongoDB and Credo Tech Group Underperform
Mar 03 2026
Barron's
Nuvalent Reports Q4 Earnings Miss with EPS of -$1.58
Feb 26 2026
seekingalpha
Nuvalent Advances Drug Launch Preparations for FDA Review
Feb 26 2026
PRnewswire
Commodore Capital Sells Nuvalent Shares in SEC Filing
Feb 23 2026
Fool
Nuvalent to Speak at Biotech Summit 2026
Feb 05 2026
PRnewswire
Nuvalent to Speak at Biotech Summit 2026
Feb 05 2026
Newsfilter
Nuvalent Submits NDA for Zidesamtinib, Targeting Approval by September 2026
Jan 12 2026
PRnewswire
Nuvalent Submits NDA for Zidesamtinib, Targeting 2026 U.S. Launch
Jan 12 2026
Newsfilter
Royalty Pharma Acquires Evrysdi Royalty for $240 Million Upfront
Dec 31 2025
Benzinga
Nuvalent CEO James Porter to Present at 2026 J.P. Morgan Healthcare Conference
Dec 22 2025
Newsfilter
Show More News
